Report
Martial Descoutures ...
  • Oussema Denguir

Recordati : Résultats T1 2024: performance opérationnelle solide et guidances réitérées

>Une profitabilité légèrement meilleure qu’attendu - Recordati a publié hier ses chiffres du 1er trimestre. Les ventes, déjà communiquées, ont augmenté de 10.9% à cc à 608 M€ sous l’impulsion des dynamiques des franchises SPC (+10.1% cc à 395.5 M€) et maladies rares (+13.9% cc à 197.5 M€) résorbant l’impact change négatif de -5.7% sous l’effet de la dévaluation de la lire turque notamment. Sur le plan opérationnel, la profitabilité ressort légèrement meilleure ...
Underlying
Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch